{
    "nctId": "NCT02536625",
    "briefTitle": "Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)",
    "officialTitle": "RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 62,
    "primaryOutcomeMeasure": "Measure of the level of Granzyme B (GzmB)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \\> 18 years old\n* Metastatic breast cancer HR+ (Hormone Receptor positive), HER2/neu negative (Human Epidermal Growth Factor Receptor-2)\n* ECOG PS (Eastern Cooperative Oncology Group Performance Status) \u22642\n* Eligible to an hormonotherapy treatment combined to an mTOR (mammalian Target Of Rapamycin) inhibitor (i.e. SPC (Summary of Product Characteristics) modalities)\n* Measurable disease according to RECIST 1.1 (Response Evaluation Criteria In Solid Tumors)\n* Not receiving the non-authorized concomitant treatments\n* Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed.\n* Patients must be covered by a medical insurance\n\nExclusion Criteria:\n\n* BMI\\>30\n* All dysimmune disease, history of transplantation or immunosuppressive therapy or corticotherapy\n* All chronic inflammatory diseases\n* Last chemotherapy \\< 6 months\n* Corticotherapy \\<1 year and more than 1 month\n* Restrictive diet \u22643 months before inclusion",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}